The pricing environment may be tough, as France announced Thursday that it had negotiated the "lowest price in Europe" for Gilead Sciences' (NASDAQ:GILD) Sovaldi, almost 40% below the U.S. price of $84,000 for a 12-week course. Much speculation has abounded over where AbbVie will price its combo upon its expected FDA approval next month
BBRY is a quandary. I can't tell if it's an emerging software company or a hardware company. The thing that really scared me is the access fee cut off and how much of its revenue these fees constitute.
I took ecology in college and understand how changes in prey population induce changes in predator population. This applies to BBRY where sales of competing products from other vendors has caused a decline in the sale of BBRY phones. BBRY has now retreated to a not so well protected niche at the bottom of a frozen river that is moving very quickly beneath the ice.
BBRY needs to merge quickly to leverage its intellectual base. It could be Intel, Google, Qcom or any of a dozen others....Just merge and save BBRY from going down drain
In its first day in the open market, Petroleo Brasiliero SA (Petrobras) managed to set a new record in a public offering, selling $67 billion in new common and preferred stock, the company reported. The company sold more than 4 billion common and preferred shares Thursday.Roughly $25 billion was sold to private investors; the Brazilian government acquired another $42.5 billion worth in exchange for giving Petrobras the right to develop rich new oil reserves. By comparison, the Agricultural Bank of China raised $22 billion in its IPO in July.
stick to GOM. Cut expenses. Be conservative
this is a long shot idea, but at high doses how quickly could AEGR's drug lower cholersterol levels to nil? the answer has to be days or it's out of consideration.
I don't think a buyout will be coming. take your cue from the offshore drillers. all is not well in the land of planty